N-[(2S,3R)-3-氨基-2-羟基-5-甲基-1-氧代己基]-L-缬氨酰-L-缬氨酰-L-天冬氨酸 | 67655-94-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 中文名称: N-[(2S,3R)-3-氨基-2-羟基-5-甲基-1-氧代己基]-L-缬氨酰-L-缬氨酰-L-天冬氨酸
• 英文名称: amastatin
• 英文别名: [(2S,2R)-3-amino-2-hydroxy-5-methylhexanoyl]-Val-Val-Asp-OH；NCGC00346895-01；(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-5-methylhexanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid
• CAS: 67655-94-1
• 化学式: C₂₁H₃₈N₄O₈
• 分子量: 474.555
• InChiKey: QFAADIRHLBXJJS-ZAZJUGBXSA-N

物化性质

• 沸点：
  795℃
• 密度：
  1.228
• 闪点：
  435℃

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  33
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.761
• 拓扑面积：
  208
• 氢给体数：
  7
• 氢受体数：
  9

安全信息

• 危险品标志：
  Xi

反应信息

• 作为产物：
  描述：

  benzyl ((1S,2S)-1-cyano-1-hydroxy-4-methylpentan-2-yl)carbamate 在 盐酸 、 palladium on activated charcoal 、 氢气 、 1-羟基苯并三唑 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 37.0h， 生成 N-[(2S,3R)-3-氨基-2-羟基-5-甲基-1-氧代己基]-L-缬氨酰-L-缬氨酰-L-天冬氨酸
  参考文献：
  名称：

  Synthesis of (2S,3R)-3-amino-2-hydroxy-5-methylhexanoic acid derivatives. Application to the synthesis of amastatin, an inhibitor of aminopeptidases

  摘要：

  DOI：

  10.1021/jo01300a004

文献信息

• Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use
  申请人：Atrin Pharmaceuticals LLC

  公开号：US20170291911A1

  公开（公告）日：2017-10-12

  The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.

  该披露涉及抑制共济失调毛细血管扩张性和Rad3相关蛋白激酶（ATR）的化合物和组合物，以及它们的使用方法。
• Synthesis and structure-activity relationships of amastatin analogues, inhibitors of aminopeptidase A.
  作者：Hiroyasu TOBE、Hajime MORISHIMA、Takaaki AOYAGI、Hamao UMEZAWA、Kunio ISHIKI、Kenji NAKAMURA、Takeo YOSHIOKA、Yasutaka SHIMAUCHI、Taiji INUI

  DOI：10.1271/bbb1961.46.1865

  日期：——

  Stereoisomers and analogues of amastatin, [(2S, 3R)-3-amino-2-hydroxy-5-methylhexanoyl]-L-Val-L-Val-L-Asp, were synthesized and their inhibitory activities towards aminopeptidase A (AP-A) and other arylamidases tested. Among the four stereoisomers of a new amino acid residue in amastatin, the 2S stereoisomers exhibited strong activity. In a series of compounds in which the C-terminal amino acid of amastatin was substituted by other amino acids, the one containing Asp or Glu showed the strongest activity towards AP-A. In a series of compounds in which the second or third residue from the amino terminal of amastatin was substituted by other amino acids, the one containing hydrophobic amino acids showed strong activity. In the study of the relationship of the length of the peptide chain and inhibitory activity, the activity towards AP-A was seen to increase until the length of the peptide reached that of a tetrapeptide.

  阿马司他（(2S,3R)-3-氨基-2-羟基-5-甲基己酰基-L-缬氨酰-L-缬氨酰-L-天冬氨酸）的立体异构体和类似物被合成，并测试了它们对氨基肽酶A（AP-A）和其他芳基酰胺酶的抑制活性。在阿马司他中一个新的氨基酸残基的四种立体异构体中，2S立体异构体表现出强烈的活性。在一系列将阿马司他C端氨基酸替换为其他氨基酸的化合物中，含有Asp或Glu的化合物对AP-A显示出最强的活性。在一系列将阿马司他从氨基端开始的第二个或第三个残基替换为其他氨基酸的化合物中，含有疏水氨基酸的化合物表现出强烈的活性。在研究肽链长度与抑制活性关系的研究中，随着肽链长度达到四肽水平，对AP-A的活性逐渐增加。
• [EN] COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS OPIACÉS CLIVABLES PAR ENZYME ET LEURS INHIBITEURS
  申请人：PHARMACOFORE INC

  公开号：WO2011133149A1

  公开（公告）日：2011-10-27

  The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.

  本公开提供了一种药物组合物及其使用方法，其中所述药物组合物包含一种前药，该前药能够提供通过酶控释放的药物，以及一种酶抑制剂，该酶抑制剂与介导从该前药酶控释放药物的酶相互作用，以减弱前药的酶裂解。本公开还提供了包含酶抑制剂和含酶可裂解基团的前药的药物组合物，所述酶可裂解基团在裂解时有助于药物的释放。
• [EN] COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS CLIVABLES PAR ENZYME DE PRINCIPES ACTIFS ET LEURS INHIBITEURS
  申请人：PHARMACOFORE INC

  公开号：WO2011133150A1

  公开（公告）日：2011-10-27

  The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.

  本公开提供了一种药物组合物及其使用方法，其中所述药物组合物包含一种前药，该前药能够提供通过酶控释放的药物，以及一种酶抑制剂，该酶抑制剂与介导药物从该前药通过酶控释放的酶相互作用，以减弱前药的酶切。本公开还提供了一种包含酶抑制剂和前药的药物组合物，所述前药包含一个酶可切割的部分，切割后可促进药物的释放。
• COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF
  申请人：Jenkins Thomas E.

  公开号：US20110262355A1

  公开（公告）日：2011-10-27

  Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

  提供的药物组合物及其使用方法，其中药物组合物包括一种阿片类药物的前药，该前药提供酶控释放的阿片类药物，以及一种酶抑制剂，该酶抑制剂与介导阿片类药物前药酶控释放的酶相互作用，以减弱对阿片类药物前药的酶切。